Wound healing
Wound healing is where GHK-Cu’s preclinical case is broadest: rat, rabbit, and irradiated-tissue models repeatedly show…
Moderate evidence, from one human trial and many animals
Wound healing is where GHK-Cu’s preclinical case is broadest: rat, rabbit, and irradiated-tissue models repeatedly show faster, better-organized healing. It also has something most peptides lack, a randomized human trial, in diabetic foot ulcers.
This unit walks that diabetic-ulcer trial, the spread of animal models, the healing phases GHK-Cu is proposed to accelerate, and the honest tier: moderate and mostly preclinical, with one good human signal that has not been broadly replicated.
Key terms
The diabetic-ulcer trial
The standout human result is a multicenter, randomized, evaluator-blinded, placebo-controlled study of a GHK-Cu gel in diabetic foot ulcers. Treated ulcers closed far more completely than vehicle, and overall closure ran several times faster than standard care.
This is genuinely good evidence by peptide standards: randomized, controlled, with a clinically meaningful endpoint. The caution is that it is one older trial in a specific wound type, and it has not been confirmed by a large body of independent human studies.
AdvancedWhat the ulcer trial actually measured
The study was multicenter, randomized, evaluator-blinded, and placebo-controlled, comparing a GHK-Cu gel against its vehicle in diabetic foot ulcers. Treated ulcers reached far higher median area closure than vehicle. That is a strong design, but it is a single older trial in one wound type, not a replicated body of human evidence.